Article info
Original research
Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors
- Correspondence to Mrs Estela García-Martín; egarciamartin{at}salud.madrid.org
Citation
Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors
Publication history
- Received October 25, 2022
- Accepted April 3, 2023
- First published April 24, 2023.
Online issue publication
August 22, 2024
Article Versions
- Previous version (24 April 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.